WO1994010330A9 - Proteine de liaison de la fibronectine et sa preparation - Google Patents
Proteine de liaison de la fibronectine et sa preparationInfo
- Publication number
- WO1994010330A9 WO1994010330A9 PCT/US1993/010547 US9310547W WO9410330A9 WO 1994010330 A9 WO1994010330 A9 WO 1994010330A9 US 9310547 W US9310547 W US 9310547W WO 9410330 A9 WO9410330 A9 WO 9410330A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- fibronectin binding
- binding protein
- polypeptide
- fibronectin
- Prior art date
Links
- 101710007977 rqcH Proteins 0.000 title claims abstract description 33
- 102000021147 fibronectin binding proteins Human genes 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title description 5
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 68
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 68
- 230000037320 fibronectin Effects 0.000 claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 31
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 25
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 18
- 235000018102 proteins Nutrition 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 10
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 239000001963 growth media Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 abstract description 4
- 200000000019 wound Diseases 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 208000004396 Mastitis Diseases 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 8
- 230000001580 bacterial Effects 0.000 description 7
- 101700013146 fnbA Proteins 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000002759 chromosomal Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108010000916 Fimbriae Proteins Proteins 0.000 description 5
- 102000007547 Laminin Human genes 0.000 description 5
- 108010085895 Laminin Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 101710043475 ATP5F1C Proteins 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101710043454 MT-ATP6 Proteins 0.000 description 4
- 101700019364 PapD Proteins 0.000 description 4
- 238000009632 agar plate Methods 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 101700037715 papC Proteins 0.000 description 4
- 101700002454 pedC Proteins 0.000 description 4
- 101700000050 pedD Proteins 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940076185 Staphylococcus aureus Drugs 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 101700068005 hbhA Proteins 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 101700034429 prsG Proteins 0.000 description 3
- 101700032180 psaA Proteins 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 210000002469 Basement Membrane Anatomy 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010009887 Colitis Diseases 0.000 description 2
- 210000002808 Connective Tissue Anatomy 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 210000002744 Extracellular Matrix Anatomy 0.000 description 2
- 229940012952 Fibrinogen Drugs 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 2
- 101700054771 GCA Proteins 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101700061402 MTRX Proteins 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 210000000214 Mouth Anatomy 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710017884 Segment-8 Proteins 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004301 light adaptation Effects 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 101700045377 mvp1 Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 101700010860 proA2 Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 1
- QGAVSDVURUSLQK-UHFFFAOYSA-N Ammonium heptamolybdate Chemical compound N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo] QGAVSDVURUSLQK-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000287523 Ara Species 0.000 description 1
- 101710044578 At3g10140 Proteins 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000002665 Bowman Capsule Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 210000003495 Flagella Anatomy 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 210000003709 Heart Valves Anatomy 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 206010022678 Intestinal infection Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710007827 RPS12 Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101710002875 TYRO3 Proteins 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 206010046577 Urinary tract infection Diseases 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 101710016654 af390-400 Proteins 0.000 description 1
- 101710016653 af470 Proteins 0.000 description 1
- 101710016491 af490 Proteins 0.000 description 1
- 101710016649 af510 Proteins 0.000 description 1
- 101710016655 af520 Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 101700005582 apaH Proteins 0.000 description 1
- 101710036446 aph Proteins 0.000 description 1
- 101710036445 aphA-6 Proteins 0.000 description 1
- 101710036449 aphA-7 Proteins 0.000 description 1
- 101710036447 aphA1 Proteins 0.000 description 1
- 101710036452 aphA4 Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 101710014658 fim Proteins 0.000 description 1
- 101700063305 fimC Proteins 0.000 description 1
- 108060002910 fimD Proteins 0.000 description 1
- 101700016793 fmpA Proteins 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 238000010358 genetic engineering technique Methods 0.000 description 1
- 101710009461 hifA Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101710036448 neo Proteins 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 101700082173 pagC Proteins 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000090 phagocyte Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 101710036430 rph Proteins 0.000 description 1
- 101710006163 sau3AIR Proteins 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- 101710033952 sloC Proteins 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Definitions
- the present invention relates to a fibronectin binding protein as well as a hybrid-DNA-molecules, e.g., plasmids and phages comprising a nucleotide sequence coding for said protein. Further the invention relates to microorganisms comprising said molecules and their use producing said protein, as well as the synthetic preparation of said protein.
- the object of the present invention is to obtain a minimal fibronectin binding protein.
- a further object of the present invention is to obtain said protein by means of a genetic engineering technique by using, e.g., a plasmid comprising a nucleotide sequence coding for said protein.
- a further object is to obtain a possibility of preparing said protein by chemical synthesis.
- WO-A1-85/05553 discloses bacterial cell surface proteins having fibronectiri, fibrinogen, collagen and/or laminin binding ability. Thereby it is shown that different bacteria have an ability to bind to fibronectin, fibrinogen, collagen and/or laminin. It is further shown that fibronectin binding protein derived from Staphylococcus aureus has a molecular weight of 165 kD and/or 87 kD, whereby it is probable that the smaller protein is a part of the larger one.
- Fibronectins are a family of high molecular weight glycoproteins occurring in a soluble form in many body fluids and in an insoluble form as a compound of cell surfaces, basement membranes, and extracellular matrices. Fibronectins appear to fulfill a critical role in clearance by phagocytes of autologous tissue debris, immune complexes, and bacteria. Fibronectins also
- SUBSTITUTE SHEET bind to epithelial cells. In doing so it may serve as a receptor for organisms like group A streptococci, but may also shield the epithelial receptors for other organisms. Thus the inability of Gramnegative organisms like Ps. aeuruginosa to colonize the oral cavity of healthy humans may be due to an interference in binding to epithelial receptors by fibronectin. The ability to resist binding to soluble fibronectin has been thought to be a virulence factor in invasive infection by group B streptococci. A number of Grampositive bacterial species including Staphylococcus aureus. other staphylococcus species, and group A, C and G streptococci exhibit specific interaction with fibronectin.
- F £ ⁇ H can express a variety of adhesins with differing binding specificities. The majority of these adhesins recognize carbohydrate moieties present on glycoconjugates.
- R. coli may also express binding to matrix proteins such as fibronectin, laminin, and collagen.
- Uropatogenic R coK expressing the 075 X adhesin bind tubular basement membranes and to the Bowman capsule known to be rich in laminin. The purified 075 X adhesin was specifically found to bind laminin.
- R coli isolated from patients with ulcerous colitis frequently bind matrix proteins.
- R coli isolates from bovine mastitis have been shown to bind to fibronectin at a high frequency. Below a native fibronectin binding protein from ⁇ eoli is disclosed, as well as the cloning of the fibronectin binding, fnbA gene from a bovine isolate of R coh that express curli pili and fibronectin binding when present in R coli HB101.
- Chemically fibronectin is a large glycoprotein (Mj about 450 kD) with two similar subunits, which may vary in molecular size depending on a complex splicing pattern of a precursor MRNA.
- the major function of fibronectin which is found in body fluids blood clots and extracellular matrices seems to be related to the ability of the protein to mediate substrate adhesion of most eukaryotic cells.
- AACTCTGCAC TTGCTCTGCA AACTGATGCC CGTAACTCTG ACTTGACTAT TACCCAGCAT GGCGGCGGTA ATGGTGCAGA TGTTGGTCAG GGCTCAGATG
- the mature curlin protein has a molecular weight of 17 kD when gel- purified, and when determined via the nucleotide sequence it is predicted to contain 122 amino acids providing for a molecular weight of 14,345 dalton.
- the invention further comprises a plasmid or phage comprising a nucleotide sequence coding for said fibronectin binding protein.
- the invention further comprises a micro-organism comprising at least one hybrid-DNA-molecule according to the above.
- the microorganism, R, coli HB101/pFnb20 encompassing the plasmid encoding for said nucleotide sequence was deposited May 05, 1988 at Deutsche Sammlung von
- the invention further comprises a method for producing a fibronectin binding protein whereby at least one hybrid-DNA-molecule of above is introduced into a micro-organism, cultivating said micro-organism in a growth medium, and isolating the protein thus formed and expressed by means of an affinity chromatography on a fibronectin bound to an insolubilized carrier followed by ion exchange chromatography.
- a further aspect of the invention comprises a chemical synthesis of the fibronectin binding protein, whereby an amino acid sequence is built up based on said nucleotide sequence encoding for said protein starting from the C- terminal amino acid which is stepwise reacted with the appropriate amino acid, whereby it is finally reacted with the amino acid at the N-terminal end, to form the fibronectin peptide region.
- carrier proteins can be coupled to the amino acid sequence as well, such as IgG binding regions of protein A.
- Bacteriophage transducing particles carrying portions of the strain AO12 genome cloned into cosmid vector pJB8 were used to transform R coli HB101.
- Strain AO12 expressed fibronectin binding when grown on CFA plates at 30°C, but to a lesser extent at 37°C. Transductants were thus
- the subclone pFnblO was digested with a series of restriction endonucleases to prepare a restriction map as shown in FIG. 1.
- pFnblO expressing fibronectin binding
- several subclones were constructed from pFnblO as were various deletion derivatives. These constructs were tested for their ability to confer binding to R. coli HB101.
- the Hpal and Sphl sites delineates the 1.2 kb region required for fibronectin binding as shown in FIG. 1.
- the recombinant plasmids shown in FIG. 1 were transformed into the minicell producing strain AA10. Plasmid encoded polypeptides were analyzed from 35 S-methionine labelled minicells.
- Plasmid pFnblO expressed two polypeptides with molecular masses of 43 kD and 17 kD respectively as shown in FIG 2.
- pFnb30 is a deletion derivative of pFnblO that lacks a 0.9 kb Clal fragment. This derivative no longer confer fibronectin binding to R coli HB101.
- the 49 kD polypeptide was still expressed from this clone but the smaller 17 kD polypeptide was missing.
- the larger polypeptide must be encoded from a gene positioned between the Clal 2 and Kpnl sites on pFnblO, since the region between Sphlj and Clal, site is to small (0.4 kb) to encompass a gene coding for a 49 kD protein.
- HB101/pFnb20 in an omnimixer and such partially purified preparations contained a dominating protein species with a molecular weight of 17 kD.
- the 17 kD polypeptide was elektroeluted onto an Immonobulon R filter and the aminoterminal sequence determined by sequential Edman degradation.
- the isolated protein was the same 17 kD gene product of the structural gene spanning the Clal. and the Hpal sites in pFnb20 this region was sequenced.
- One open reading frame consisting of 133 codons was identified spanning the Clal and Hpal sites.
- the protein sequence of the 5 amino terminal residues was identical to the DNA sequence specified by codons 2-6 in the open reading frame confirming that the open reading frame identified encodes the subunit protein of the coiled surface structure.
- the name "curlin” is proposed for this subunit protein, curli for the structure and csga for the structural gene.
- the curlin subunit appears to be strictly different from R coH pilins and coH pilins have several features in common such as cleavable signal peptide, two cysteine in the amino-terminal half, and several conserved amino acids in the amino and carboxy terminal regions thought to be involved in the subunit interactions. Likewise no homologoes were found with the N-methyl Phe class of pilus expressed by Neisseria gonorrhoeae and many other Gram negative species. Flagellin is not a true secretary protein since it is
- Sequence analysis of a CsCl 2 -purified double-stranded plasmid DNA from pCSG4 was performed by denaturing approximately 4 ug of DNA with 2 M NaOH/2 mM EDTA and neutralizing it with 7.5 M ammonium acetate (pH 5). Appropriate oligonucleotides (1 pmole) were annealed to alkalidenatured DNA and sequenced using the Sequenase R protocol as described by the manufacturer (United States Biochemical, Cleveland, OH). Electrophoresis was performed in a 90 mM TEE buffer system for 2-5 hra at 45 mA in 8 M urea/6% polyacrylamide gels. Gels were fixed, dried, and exposed to Hyperfilm (Amersham).
- R coli HB101 has been used as a host to clone and express a number of R coli pili types. In no other case it has been possible to obtain surface located pili by only expressing the pilin gene. All other known gene cluster
- SUBSTITUTE SHEt i that have been examined today contain additional genes required for transport and assembly of the pilus fiber.
- plasmid pFnb20 was present in R coli AA10 curli pili were not observed at 26°C as shown in FIG. 7 and the cells did not bind fibronectin.
- Most R coli strains carry in their chromosome, genes for type 1 pili. Both R coli HblOl and AA10 are unable to form such pili. In the former strain some genes from the type 1 operon are still functioning whereas the entire type 1 gene cluster is deleted in AA10.
- Plasmid pSJH9 carries all accessory genes required for type 1 pilus formation but is deleted for the fimA gene encoding the major pilin subunit.
- AA10 harboring plasmid pSJH9 and pFnb20 did not bind fibronectin.
- the ability of pFnb20 to express fibronectin binding and curli pili in HB101 does not seem to depend on the comnlementation from chromosomal type 1 pilus genes.
- accessory genes located close to fnba could confer fibronectin binding to R c ⁇ ji AA10 this strain was transformed with the original cosmid clone pAO450.
- strain AA10/pAO450 was not expressing fibronectin binding.
- Minicell experiments revealed that strain AAIO is able to synthesize the FnbA protein at 26 °C as well as at 37° C. It is therefore concluded that the FnbA protein cannot be expressed for surface localization, nor be assembled into curli pili in this strain.
- Escherichia coli is a common cause of bovine mastitis.
- R. coli milk isolates from cases of acute mastitis do not differ from the normal faecal R coli flora in the cow.
- the ability to bind to fibronectin stands out as a common property shared by 50-80% of the isolates studied.
- the fnbA gene was cloned and characterized.
- the fnb gene codes for a 17,000 dalton protein that is able to polymerize into curli pili-like structures when expressed in R. coH HblOl.
- R coli pili are encoded from an operon consisting of 11 pap genes.
- SUBSTITUTE SHEET outer membrane pore protein, and papD expressing a 28 kD periplasmic transport protein are needed in addition to pap A, the major subunit gene to form surface located pili. Even though other classes of pill adhesin genecluster appear to be less complex and contain fewer genes than the pap system all carry genes functionally equivalent to papC and papD.
- R coH HB101 express the accessory proteins required for the biogenesis of curli Fnb pili. It is known that R coH HB101 carry some DNA that hybridize to cloned type 1 DNA. However, R coU HB101 do not express type 1 pili if transformed with a type 1 clone deleted for either the fimD (the papC equivalent) or the fimC (the papD equivalent) gene. It is therefore unlikely that it is chromosomal type 1 DNA that encodes the accessory proteins required for the formation of curli Fnb pili.
- Curli Fnb pili are formed in HB101 at 26°C but not at 37°C.
- the Fnb protein is synthesized to the same extent at both temperatures. It is thus suggested that the temperature regulation of piliation and fibronectin binding do not operate at the level of transcription but at the level of pilus biogenesis.
- Pap pili and many other virulence associated properties are also temperature regulated but the effect of incubation tempera ⁇ ture is the reverse of what has been observed concerning the Fnb pili. In these former system transcription is increased with an increased temperature.
- SUBSTITUTE SHEET This kind of temperature regulation is thought to reflect the adaptation of the micro-organism to the mammalian host.
- Wound pathogens such as Staphylococcus aureus and Staphylococcus genera frequently bind to fibronectin.
- the temperature of the skin is lower than 37°C. If fibronectin binding of R coH also reflects an adaptation to bind to wounds on the exterior of the host it would be an advantage for the micro ⁇ organism to have optimal binding at a temperature lower than 37°C.
- Fibronectin binding curli pili actually plays a role in the pathogenesis of bovine mastitis.
- the frequent presence of ulcers, due for example to machine milking on the udder might, however, enable colonization of fibronectin binding I coli.
- Fibronectin is a large glycoprotein known to bind to a large set of proteins. It is therefore uncertain how specific the interaction is between fibronectin and Fnb pili.
- the fnbA cosmid pAO450 was the single one out of 560 cosmids tested that expressed fibronectin binding in HB101. It is thus believed that this gene is the sole determinant of fibronectin binding in R. c ji AO12.
- Strain A012 is a bovine faecal isolate obtained from a healthy cow.
- Bacteria were normally grown in L-broth (Bertani 1951).
- For the fibronectin binding assay bacteria were grown on CFA-agar (Evans, Inf. and Imm.. 21, 738-748) and containing 0.005% magnesium sulphate and 0-0005% magnesium chloride in 2% Bacto agar (Difco).
- Competent cells for transformation were prepared with 50 mM CaCl 2 (Gene 6, 23-28, Dagert).
- the antibiotics ampicillin (100 / ug/ml), kanamycin (50 / ug/ml) and chloramphenicol (20 / ug/ml) were used for selection of plasmid-containing strains. Unless otherwise stated, incubation of bacterial cultures was carried out at 37°C.
- the present fibronectin binding protein will sometimes be synthesized in the cell wall and is not expressed as a pili. This protein thus synthesized can be isolated as well by known biochemical methods, such as affinity chromatography.
- SUBSTITUTE SHEET fragments were subcloned into M13mplB and M13mpl9 vector (Messing, J and Nieira, J. Gene.. 19, 269-272 (1982)), and sequenced using the dideoxy chain terminating method of Sanger et al, P ⁇ AS. 74, 5463-5467.
- D ⁇ A sequencing the bacteriophage T7 D ⁇ A polymerase, and SequenaseTM were used.
- the primer used was Universal M13 17mer and synthesized 20mer oligonucleotides supplied by Symbicom, Umea, Sweden.
- D ⁇ A was isolated as described by Lund et al. Plasmid D ⁇ A from clones carrying recombinant D ⁇ A was isolated by the alkaline lysis procedure (Maniatis, CSH, ⁇ .Y., USA).
- Chromosomal DNA purified from R coH A012 were partially cleaved with endonuclease Sau3AI.
- the DNA was size fractionated on a 10-40% linear sucrose gradient. Fractions containing DNA fragments larger than 20 kb in size were pooled and ligated into the BamHI site of the cosmid vector pJB8 as described by Maniatis, CSH Lab, N.Y., USA. Recombinant molecules were packaged in vitro into particles using a lambda DNA in vitro packaging kit (code N.334, Amersham). The phage was then used to infect R. coU HB101 by selecting for ampicillin resistant clones after growth on CFA agar plates at 30°C for 40-48 hrs.
- Plasmid pFnbOl was constructed by subcloning a 4.9 kb large Sail fragment from this cosmid into pACYC184. An internal 3 kb large Sphl r Kpnl from pFnbOl was cloned into pUC18 (Messing) giving pFnblO. A number of subclones from pFnblO were generated by cloning into the polylinker site in pUC18. Plasmid pFnb59 is a Clal cutback derivative of
- pFnblO SUBSTITUTE SHEET pFnblO.
- Subclones were constructed as follows.
- pFnblO consists of the 3.0 kb Kpnl-Pstl fragment of the original clone ligated into the polylinker cloning cassette of pUC18, while pFnb3O is a Clal deletion derivative of pFnblO.
- Plasmid pFnb20 was obtained by cloning the 1.5 kb Sphl-B lll fragment from the original plasmid into pUCl ⁇ . Analysis of this construct which lacks the 5' terminal end of the gene coding for the 49 kD peptide showed that this protein was not necessary for curli production or for fibronectin binding.
- Plasmids pFnb56 and pFnb46 are SphlHpal and Clal-Bgi ⁇ subclones, respectively of pFnblO in pUC18. Plasmid pFnb59 was obtained by first subcloning the Kpnl-Bgi ⁇ fragment of the original plasmid in pUC18 and then inserting the aminoglycoside-3'-phosphotransf erase gene (APH) from the mobilization plasmid pUC4K into the Clal ! site. To perform the fibronectin binding assay bacteria were grown an CFA-agar plates for 42-48 hrs at 26°C or 37°C.
- APH aminoglycoside-3'-phosphotransf erase gene
- Accl digested plasmid pUC-4K (Pharmacia, Uppsala, Sweden) carrying the kanamycin resistance gene from transposon Tn903 coding for aminoglycoside 3 phosphotransferase (APH) was ligated to Clal digested pFnb56.
- Transformants in HB101 were screened for ampicillin and kanamycin resistance.
- One such clone carrying the Kana R fragment at the Clal site was denoted pFnb59.
- the fibronectin binding assay was a modification of the procedure described by G. Froman et al, (JBC, 259, 14899-14905). Bacteria were inoculated on CFA plates for 42-48 hrs at 26°C or 37°C. Cells were resuspended in cold phosphate-buffered saline (pH 7.5) to an optimal density of 10 9 cfu/ml. 100 ul of cells were added to an assay tube containing 1 ml of PBS + 0-1 % Tween 80 + 100 /ul of 125 I-fibronectin (5x10 s cpm) and the mixture was end over incubated in room temperature for 1 hr. Tubes were centrifuged in Eppendorf centrifuge for five min. Supematants were carefully
- Plasmid constructs were transformed into the minicell-producing strain AAIO. Preparation and labelling of minicells with 35 S-methionine were as described by Thompson and Achtman (Mol. Gen. Genet. 165. 295-304 (1978)).
- radioactive samples were separated on linear 15 % (wt vol) SDS- polyacrylamide gels (Laemmli, UK, Nature. 227. 880-885, (1970)). The gels were fixed, stained, destained, and exposed to X-ray film (DuPont) for 1-5 days. Molecular weight standards were from Pharmacia Fine Chemicals, Uppsala, Sweden.
- Precursor form of proteins encoded by different constructions were monitored after radiolabelling of minicells in the presence of 9% ethanol (Palva, J. Bact.. 146. 325-330) and analyzed on SDS-polyacrylamide gels.
- Electron microscopy was performed using a JEOL 100B microscope with 100-mesh copper grids coated with thin films of 2% Formvar. Bacteria from CFA agar plates were resuspended in 10 mM Tris-HCl,-pH 7.5 + 10 mM MgCl 2 , and placed on the grid. Grids were washed with buffer and negatively stained for 5 sec. with 3.55% ammonium molybdate, followed by washing with redistilled water.
- the present fibronectin binding protein can be used for immunization, whereby the protein, preferably in combination with a fusion protein to create a large antigen to respond to, or the pili shaken off from the R coH expressing the curli pili when grown around about 30 °C, preferably at 26°C, or the inactivated R coli comprising the curli pili consisting of the fibronectin binding 17 kD protein, is injected in dosages causing immunological reaction in the host mammal.
- the fibronectin preferably in combination with a fusion protein to create a large antigen to respond to, or the pili shaken off from the R coH expressing the curli pili when grown around about 30 °C, preferably at 26°C, or the inactivated R coli comprising the curli pili consisting of the fibronectin binding 17 kD protein
- SUBSTITUTE SHEET binding protein can be used in vaccination of ruminants against mastitis caused by R coH infections.
- the fibronectin binding protein can further be used for immunization against urinary tract infections, normally caused by R coH, or intestinal infections normally caused by R cpji, such as ulcerous colitis.
- the fibronectin binding protein of this invention has shown to form antibodies against R cjp ⁇ related infections.
- the fibronectin binding protein can be used to block an infection in an open skin wound by wound treatment using the fibronectin binding protein in a suspension.
- the fibronectin binding protein can be used for the treatment of wounds, e.g., for blocking protein receptors, or for immunization (vaccination).
- the host body produces specific antibodies which can protect against invasion of bacterial strains comprising such a fibronectin binding protein.
- the antibodies block the adherence of the bacterial strains to damaged tissue.
- colonizing of tissue damage examples include: a) colonizing of wounds in skin and connective tissue, which wounds have been caused by a mechanical trauma, chemical damage, and/or thermical damage; b) colonizing of wounds on mucous membranes such as in the mouth cavity, or in the mammary glands, urethra, or vagina; c) colonizing on connective tissue proteins, which have been ex ⁇ posed by minimal tissue damage (micro lesion) in connection with epithelium and endothelium (mastitis, heart valve infection, hip exchange surgery).
- minimal tissue damage micro lesion
- the protein, or polypeptide, or curli pili, or whole inactivated bacteria is dispersed in sterile, isotonic saline solution, optionally while adding a pharmaceutically acceptable dispersing agent.
- sterile, isotonic saline solution optionally while adding a pharmaceutically acceptable dispersing agent.
- adjuvants can further be used in order to sustain the release in the tissue, and thus expose the protein for a longer time to the immuno defense system of
- a suitable dosage to obtain immunization is 0.5 to 5 ug of fnb protein per kg bodyweight and injection of immunization.
- vaccinations should be carried out at more than one consecutive occasions with an interval of 1 to 3 weeks, preferably at three occasions.
- the protein When using the present fnb protein for topical local administration the protein is dispersed in an isotonic saline solution to a concentration of 25 to 250 u per ml. The wounds are then treated with such an amount only to obtain a complete wetting of the wound surface. For an average wound thus only a couple of milliliters of solution are used in this way. After treatment using the protein solution the wounds are suitably washed with isotonic saline or another suitable wound treatment solution.
- fibronectin binding protein, or the synthesized polypeptide of the present invention can be used to diagnose bacterial infections caused by R. coU strains, whereby a fibronectin binding protein of the present invention is immobilized on a solid carrier, such as small latex or Sepharose R beads, whereupon sera containing antibodies are allowed to pass and react with the fibronectin binding protein thus immobilized. The agglutination is then measured by known methods.
- a solid carrier such as small latex or Sepharose R beads
- fibronectin binding protein or the polypeptide can be used in ELISA test (E. Engvall, "Enzyme Linked Immuno Sorbent Assay," Med. Biol. 55, 193, (1977)).
- ELISA test E. Engvall, "Enzyme Linked Immuno Sorbent Assay," Med. Biol. 55, 193, (1977)
- wells in a polystyrene microtitre plates are coated with the fnb protein and incubated over night at 4°C. The plates are then thoroughly washed using PBS containing 0.05% Tween 20, and dried. Serial dilution of the patient serum is made in PBS-Tween, are added to the wells, and incubated at 30°C for 1.5 hrs.
- antihuman-IgG conjugated with an enzyme or a horseradish peroxidase, or an alkaline phosphatase is added to the wells and incubated at 300°C for 1.5 hrs., whereupon when the IgG has been bound thereto, and after rinsing, an enzyme, or a horseradish peroxidase, or an alkaline phosphatase is added to the wells and incubated at 300°C for 1.5 hrs., whereupon when the IgG has been bound thereto, and after rinsing, an enzyme, or a horseradish peroxidase, or an alkaline phosphatase is added to the wells and incubated at 300°C for 1.5 hrs., whereupon when the IgG has been bound thereto, and after rinsing, an enzyme, or a horseradish peroxidase, or an alkaline phosphatase is added to the wells and incubated at 300°C for 1.5 hrs.,
- SUBSTITUTE SHEET enzyme substrate is added, a p-nitrophosphate in case of an alkaline phosphatase, or orthophenylene diamine substrate (OPD) in case a peroxidase has been used, respectively.
- the plates comprising the wells are thus then rinsed using a citrate buffer containing 0.05S% OPD, and 0,005% H 2 O 2 , and incubated at 30°C for 10 min. Enzyme reaction is stopped by adding a 4N solution of H 2 SO 4 to each well. The color development is measured using a spectrophotometer.
- fibronectin binding protein includes any of the polypeptide sequences as well, which polypeptide sequences form the minimal fibronectin binding site of the complete protein.
- Figure legends Figure 1 Physical map of the different pFnb plasmid constructs. Fnb-f- or - indicate fibronectin binding phenotype. Constructs: pFnblO SphI r KpnI fragment in pUC18
- Figure 2 Restriction map and gene organization of fnb gene. The hatched boxes indicate the 17 kD.
- Electron microscopy was performed with a JOEL 100B microscope with 100-mesh copper grids coated with thin films of 2% Formvar. Bacteria from CFA-agar plates were resuspended in lOmM tris-HCl, pH 7,5-lOmM MgCl 2 and placed on the grid. Grids were washed with buffer and negatively stained for 5 sec. with 3.55% ammonium molybate, followed by washing with redistilled water.
Abstract
La présente invention se rapporte à une nouvelle protéine de liaison de la fibronectine à partir d'E. coli se présentant sous la forme de curli pili, une nouvelle molécule d'ADN hybride recombinée comprenant une séquence nucléotidique à partir d'E. coli codant pour une protéine ou un polypeptide ayant des propriétés de liaison de la fibronectine.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU55907/94A AU692140B2 (en) | 1992-11-03 | 1993-11-03 | Fibronectin binding protein as well as its preparation |
NO951679A NO951679L (no) | 1992-11-03 | 1995-05-02 | Fibronektin-bindende protein, samt fremstilling derav |
FI952108A FI952108A (fi) | 1992-11-03 | 1995-05-03 | Fibronnektiiniä sitova proteiini sekä sen valmistaminen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97084692A | 1992-11-03 | 1992-11-03 | |
US07/970,846 | 1992-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994010330A1 WO1994010330A1 (fr) | 1994-05-11 |
WO1994010330A9 true WO1994010330A9 (fr) | 1994-06-23 |
Family
ID=25517597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/010547 WO1994010330A1 (fr) | 1992-11-03 | 1993-11-03 | Proteine de liaison de la fibronectine et sa preparation |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU692140B2 (fr) |
CA (1) | CA2148479A1 (fr) |
FI (1) | FI952108A (fr) |
NO (1) | NO951679L (fr) |
WO (1) | WO1994010330A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685943B1 (en) | 1997-01-21 | 2004-02-03 | The Texas A&M University System | Fibronectin binding protein compositions and methods of use |
ATE342990T1 (de) | 2001-08-10 | 2006-11-15 | Bioleaders Corp | Oberflächenexpressionsvektoren mit pgsbca, dem für poly-gamma-glutamat-synthetase codierenden gen, sowie verfahren zur expression eines zielproteins an der oberfläche eines den vektor benutzenden mikroorganismus |
GB0202275D0 (en) * | 2002-01-31 | 2002-03-20 | Hansa Medica Ab | Peptide |
KR20200000972A (ko) | 2018-06-26 | 2020-01-06 | 주식회사 바이오리더스 | 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를 이용한 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 |
JP7147060B2 (ja) | 2018-10-10 | 2022-10-04 | バイオリーダース コーポレイション | ラクトバチルス・カゼイ由来ガラクトース・ムタロターゼ遺伝子のプロモーターを用いた常時的高発現表面発現ベクターおよびその利用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8801723D0 (sv) * | 1988-05-06 | 1988-05-06 | Staffan Normark | Fibronectin binding protein as well as its preparation |
-
1993
- 1993-11-03 AU AU55907/94A patent/AU692140B2/en not_active Expired
- 1993-11-03 WO PCT/US1993/010547 patent/WO1994010330A1/fr active Application Filing
- 1993-11-03 CA CA002148479A patent/CA2148479A1/fr not_active Abandoned
-
1995
- 1995-05-02 NO NO951679A patent/NO951679L/no not_active Application Discontinuation
- 1995-05-03 FI FI952108A patent/FI952108A/fi unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5804198A (en) | Vaccines against disease caused by pathogenic pilus-forming bacteria | |
FI113009B (fi) | Menetelmä rokotteen valmistamiseksi Neisseria meningitidis-bakteeria vastaan sekä Neisseria meningitidis -kanta | |
AU679911B2 (en) | DNA fragments which encode the transferrin receptor subunits of Neisseria meningitidis | |
US5866541A (en) | Fibronection binding protein from Streptococcus dysgalactiae | |
Young et al. | Sequence, localization and function of the invasin protein of Yersinia enterocoiitica | |
US5958736A (en) | Recombinant DNA coding for signal peptide, selective interacting polypeptide and membrane anchoring sequence | |
AU618803B2 (en) | Pharmaceutical composition containing fibronectin binding protein | |
US5789549A (en) | Fibronectin binding protein | |
FI105333B (fi) | Kollageeniä sitova proteiini tai polypeptidi sekä sen valmistaminen | |
Tennent et al. | Integrity of Escherichia coli P pili during biogenesis: properties and role of PapJ | |
US6030805A (en) | Fibronectin binding protein as well as its preparation | |
AU692140B2 (en) | Fibronectin binding protein as well as its preparation | |
WO1994010330A9 (fr) | Proteine de liaison de la fibronectine et sa preparation | |
US6015889A (en) | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition | |
EP1029054A1 (fr) | Hp90: recepteur hote a membrane pour bacteries pathogenes codees par le gene bacterien tir | |
US7208574B1 (en) | Host receptor for pathogenic bacteria | |
US20040096965A9 (en) | Activator of fibronectin binding protein and method of its preparation | |
WO1999029724A9 (fr) | ADN CODANT UNE PROTEINE MEMBRANAIRE EXTERIEURE DE $i(PASTEURELLA MULTOCIDA) | |
WO1992001703A1 (fr) | Production de l'antigene majeur de piline cs1 et compositions pour ce dernier comprenant des vaccins et des sondes diagnostiques | |
IE83742B1 (en) | Fibronectin binding protein |